trial

A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia

NCTId NCT00640510
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 34 (actual)
Sponsored by Eli Lilly and Company
Primary completion 2008-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-03
Primary completion
2008-07
Eligibility
ALL · 20 Years · 64 Years

Interventions & indications

Drugs
OlanzapineIsotonic sodium chloride solution

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

11 total
Fukushima, JapanGunma, JapanKagoshima, JapanKanagawa, JapanKumamoto, JapanOkayama, JapanOkinawa, JapanSaga, JapanTokyo, JapanTottori, JapanYamagata, Japan

Linked catalysts

1
A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated — primary completion2008-07

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE3
Primary Completion Date
2008-07
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Isotonic sodium chloride solution
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person